MSD’s expanding non-oncology portfolio is expected to play an increasingly important role in cushioning the impact of Keytruda’s patent cliff.
This shift indicates a strategic pivot for MSD as it prepares for the potential revenue decline associated with the loss of exclusivity for Keytruda. By doubling its focus on non-oncology sales, MSD may mitigate financial risks and maintain market presence. This could influence manufacturers and suppliers in the oncology sector to reassess their strategies in light of changing market dynamics.
Source: pharmaceutical-technology.com · Image: SDI, Samarra – Dec 21, 2019 12 by قناة التغيير, CC BY 3.0, via Wikimedia Commons
Explore deeper: the API & FDF Intelligence database is more than a directory.
It combines global coverage of APIs, excipients, and finished dosage forms with real market intelligence.
You’ll find:
– Price ranges for APIs, excipients, and formulations.
– DMF, CEP, and GMP compliance status.
– Manufacturer portfolios by product and geography.
– Direct contacts for every producer and FDF holder, ready for outreach.
Instead of scattered spreadsheets and endless searches, the entire picture is a few clicks away. Subscription starts at an accessible rate — see how much time and budget you save by centralizing everything.
Start your 7-day trial and see what the database can do →
Start your 7-day trial and see what the database can do →
